Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients
An Open-label, Randomised, Four Period Crossover Study to Investigate the Relative Pharmacokinetic Profiles of Tablets From Three Batches of Firategrast With Different Surface Areas and Two Different Tablet Formulations Containing the Same Batch of Firategrast, Given as Single 900mg Doses to Male and Female Subjects With a Diagnosis of Multiple Sclerosis An Open-label, Randomised, Four Period Crossover Study to Investigate the Relative Pharmacokinetic P ...
Multiple Sclerosis
Drug: Formulation A;Drug: Formulation B;Drug: Formulation C;Drug: Formulation D